2009
DOI: 10.1089/jop.2008.0026
|View full text |Cite
|
Sign up to set email alerts
|

Protecting the Ocular Surface and Improving the Quality of Life of Dry Eye Patients: A Study of the Efficacy of an HP-Guar Containing Ocular Lubricant in a Population of Dry Eye Patients

Abstract: The improvements in ocular surface staining and dry eye symptoms with the HPG containing ocular lubricant -- evident as early as the first follow-up visit (Day 7) and continued throughout the 28 days of the study with a concurrent, increase in OPI to a level greater than unity -- indicate that this preparation is a fast-acting, long-lasting, and effective treatment for dry eye. In concurrence with the results from previously published clinical studies, the HPG containing ocular lubricant has shown efficacy in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
18
0
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 37 publications
(20 citation statements)
references
References 24 publications
1
18
0
1
Order By: Relevance
“…16,18 A number of AT preparations claim to enhance tear film stability, decrease evaporative tear loss, or confer osmoprotective effects. [18][19][20][21] Cyclosporine A (CsA) is an established systemic immunosuppressive agent, approved in topical (tCsA) emulsion formulation (Restasis, Allergan, Irvine, CA) for topical therapy of KCS and recommended for the treatment of moderate-tosevere inflammation, level 2 or higher, associated with DES. 16 On the ocular surface, tCsA acts as an immunomodulator, downregulating T-cell activity without any documentation of increased infection risk or immunosuppression.…”
mentioning
confidence: 99%
“…16,18 A number of AT preparations claim to enhance tear film stability, decrease evaporative tear loss, or confer osmoprotective effects. [18][19][20][21] Cyclosporine A (CsA) is an established systemic immunosuppressive agent, approved in topical (tCsA) emulsion formulation (Restasis, Allergan, Irvine, CA) for topical therapy of KCS and recommended for the treatment of moderate-tosevere inflammation, level 2 or higher, associated with DES. 16 On the ocular surface, tCsA acts as an immunomodulator, downregulating T-cell activity without any documentation of increased infection risk or immunosuppression.…”
mentioning
confidence: 99%
“…O tratamento com suplementação alimentar a base de ácidos graxos insaturados essenciais tipo ômega 3 tem se mostrado eficaz em diversos estudos (41)(42)(43) . O uso de colírio lubrificante a base de HP Guar é indicado no tratamento de disfunção lacrimal, principalmente se estiver relacionado com ceratopatia ponteada, bem como alterações da camada mucóide do filme lacrimal (44)(45) . Relatamos um caso de hipertensão ocular associado à edema de córnea após cirurgia de catarata em que a medida da pressão ocular por meio de TAG era hipoestimado.…”
Section: Discussionunclassified
“…Unfortunately the ideal non crust forming and stability improving gelling agent has not yet been developed. It seems that hydroxypropyl-guar possess more specific adhesive properties to injured ocular surfaces [35][36][37].…”
Section: Improvement Of Tear Film Stabilitymentioning
confidence: 99%
“…Apart from the polymers mentioned in Table 10.6 some authorised medicines contain other viscosity enhancing agents such as dextran, hydroxyethylcellulose, hyaluronic acid and hydroxypropylguar gum (HP-guar; Systane®) [36,37,57]. Hyaluronic acid possesses good adhesive properties.…”
Section: Viscosity Enhancing Polymersmentioning
confidence: 99%